Cash-strapped Alligator Biosciences is reducing its workforce and early-stage activities to put all its focus on preparing its pancreatic cancer candidate, mitazalimab, for Phase III trials.
Sweden’s Alligator Makes Cuts To Avoid Extinction
The company’s CD40 agonist mitazalimab has impressed in Phase II trials as a potential treatment for pancreatic cancer but with no partner in place yet and a lack of funds, Alligator has to cut 70% of its staff to keep going.
More from Financing
More from Therapy Areas
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.